Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Cash flows from operating activities:
Net (loss) income	$ (61,833)	$ 3,070	$ 338
Adjustments to reconcile net (loss) income to net cash (used in) operating activities:
Amortization of premium or discount on fixed maturity securities	574	1,663	2,309
Net realized (gain) loss on sale of investments	(324)	(436)	1,575
Unrealized loss on trading securities	463	774	3,492
Unrealized loss on derivative liability - embedded conversion feature	54,621
Equity-based compensation expense	1,129	807	401
Changes in assets and liabilities:
Accrued investment income	241	634	588
Other assets	157	586	338
Change in cash equivalents held in trust	7,435	21,971	(16,074)
Change in restricted cash	(568,993)	(2,332)	25,054
Losses and loss adjustment reserves	(13,884)	(25,367)	(38,210)
Losses payable	(291)	(1,821)	377
Unearned premiums	(333)	(300)	1,169
Accrued ceding commission expense	(11)	(58)	(34)
Accrued interest on notes payable	(102)	(805)	(333)
Loss contract fair market value reserve	(2,926)	(33,770)	(5,898)
Other liabilities	904	1,803	682
Total adjustments	(521,340)	(36,651)	(24,564)
Net cash (used in) operating activities:	(583,173)	(33,581)	(24,226)
Cash flows from investing activities:
Purchase of investments	(269,694)	(511,103)	(430,983)
Proceeds from sales and maturities of investments	230,567	667,262	482,275
Net cash (used in) provided by investing activities:	(39,127)	156,159	51,292
Cash flows from financing activities:
Proceeds from issuance of preferred stock and warrants to purchase common stock	600,000	22,572
Fees incurred and paid relating to preferred stock and warrant issuance	(19,310)	(3,348)
Redeemable convertible series B preferred stock dividends paid in cash	(16,998)
Deferred offering costs		(1,497)	(1,071)
Notes payable – principal repayments	(10,395)	(78,890)	(36,294)
Notes payable – principal issued	918	4,608	5,524
Net cash provided by (used in) financing activities:	554,215	(56,555)	(31,841)
(Decrease) increase in cash and cash equivalents	(68,085)	66,023	(4,775)
Cash and cash equivalents, beginning of period	78,009	11,986	16,761
Cash and cash equivalents, end of period	9,924	78,009	11,986
Supplementary disclosure of cash flow information:
Cash paid during the period, Interest	2,887	18,272	9,707
Supplementary disclosure of non-cash investing and financing activities:
Embedded derivatives on preferred stock issuances	66,227
Notes payable issued in lieu of cash interest payments	918	4,608	$ 5,524
Non-cash redeemable convertible series B preferred stock dividends accrued	750
Accrued fees relating to series B preferred stock issuance	$ 12,250
Preferred deemed dividend recorded due to beneficial conversion feature		$ 9,455